PV or ET patient elderly or frail (age ≥80, ECOG ≥3, multiple comorbidities, life expecta...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-PV-ET-FRAILTY-AGE |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-ET DIS-PV |
| Sources | SRC-ESMO-MPN-2015 SRC-NCCN-MPN-2025 |
Red Flag Origin
| Definition | PV or ET patient elderly or frail (age ≥80, ECOG ≥3, multiple comorbidities, life expectancy <5 years) — gentler cytoreduction (lower HU dose), expanded transfusion + monitoring strategy |
|---|---|
| Clinical direction | de-escalate |
| Category | frailty-age |
Trigger Logic
{
"any_of": [
{
"comparator": ">=",
"finding": "age_years",
"threshold": 80
},
{
"finding": "mpn_frail_unfit",
"value": true
}
],
"type": "composite"
}
Notes
Direction "investigate"-equivalent — surfaces dose-attenuation annotation; does not switch indication. Older patients tolerate HU well long-term but the leukemogenic-conversion concern weighs less; choice often defaults to HU 1L regardless of age. STUB — requires clinical co-lead signoff.
Used By
Algorithms
ALGO-ET-1L- ALGO-ET-1LALGO-PV-1L- ALGO-PV-1LALGO-PV-2L- ALGO-PV-2L
Indications
IND-ET-1L-ASA- IND-ET-1L-ASAIND-ET-1L-HU- IND-ET-1L-HUIND-ET-2L-ANAGRELIDE- IND-ET-2L-ANAGRELIDEIND-PV-1L-HU- IND-PV-1L-HUIND-PV-1L-ROPEGINTERFERON- IND-PV-1L-ROPEGINTERFERON